The role of ERRalpha/PGC-1 in disease pathogenesis
The role of ERRalpha/PGC-1 in disease pathogenesis
批准号:
8459862
负责人:
Donald P McDonnell
金额:
$32.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2018-01-31
关键词:
AdipocytesBiomassBreast Cancer ModelCell modelCellsCharacteristicsCitric Acid CycleClinicalComplexDataDiseaseDistantERBB2 geneERR1 proteinEnvironmentEnzymesExtracellular Matrix ProteinsGene ExpressionGene TargetingGenerationsGenesGlucoseGrowthGrowth FactorGrowth Factor OncogenesHomeostasisMaintenanceMalignant NeoplasmsMammary NeoplasmsMediatingMetabolicMetabolic PathwayMetabolismMouse Mammary Tumor VirusMuscleNeoplasm MetastasisNuclear Orphan ReceptorNuclear ReceptorsNutrientOncogenesOutcomeOxygen measurement, partial pressure, arterialPPAR gammaPathogenesisPathway interactionsPhysiologicalPhysiologyProcessProductionProliferatingProteinsQuantitative EvaluationsRegulationRoleSiteTestingTherapeuticTherapeutic InterventionTissuesUp-RegulationVascular Endothelial Growth FactorsWNT11 geneWorkXenograft ModelXenograft procedureangiogenesisbasecancer cellcell transformationinsightmalignant breast neoplasmosteopontinovarian neoplasmpublic health relevancereceptorresponsetherapeutic targettooltriple-negative invasive breast carcinomatumortumor growthtumor initiationtumor microenvironmenttumor progression
中文摘要
描述(由申请人提供):雌激素相关受体α (ERR¿)是一种孤儿核受体,其转录活性受其专性共调节剂PGC-1¿或PGC-1¿的表达水平和/或活性调节。在正常生理条件下,ERR¿/PGC-1复合体参与调节能量需求高的组织的代谢稳态。由于观察到ERR¿在乳腺和卵巢肿瘤中的表达升高与较差的临床结果相关,我们开发了一种基因标记(metagene),允许对肿瘤中的ERR¿活性进行定量评估。使用该工具,确定ERR¿活动在所有乳腺中都明显存在
英文摘要
DESCRIPTION (provided by applicant): The Estrogen Related Receptor alpha (ERR¿) is an orphan nuclear receptor whose transcriptional activity is regulated by the expression level and/or activity of its obligate coregulators PGC-1¿ or PGC-1¿. Under normal physiological conditions, the ERR¿/PGC-1 complex is involved in regulating metabolic homeostasis in tissues in which energy demand is high. Motivated by the observation that elevated expression of ERR¿ in both breast and ovarian tumors is associated with a poor clinical outcome, we developed a gene signature (metagene) that permitted a quantitative evaluation of ERR¿ activity in tumors. Using this tool, it was determined that ERR¿ activity is manifest in all breast
tumor sub-types with particularly high activity being evident in ER¿-negative, HER2 positive, and triple negative breast cancers where it predicts a negative outcome. A causal role for ERR¿ in breast cancer growth was confirmed in both cellular and xenograft models of breast cancer. Interestingly, it was also demonstrated that growth factor and/or PI3K-dependent activation of ERR¿/PGC-1 induces the expression of genes required for metabolic reprogramming in transformed cells and genes involved in angiogenesis, metastasis, and the establishment of the tumor microenvironment. Hypothesis: We propose that growth factor/oncogene-mediated upregulation of PGC-1¿ and/or PGC-1¿ expression results in the ERR¿-dependent activation of processes that contribute to tumor growth and metastasis. Specifically, it is hypothesized that this receptor contributes to cellular biomass accumulation by inducing the expression of key gene products required for the generation of biosynthetic intermediates and those which enable the adaptive responses underlying the differential use of glucose and lactate by cells in different
tumor environments. ERR¿ further reinforces these metabolic responses by regulating processes involved in (a) the establishment and maintenance of the tumor microenvironment, (b) angiogenesis, and (c) facilitating distant site metastasis. Specific Aims Aim 1: Define the rol of ERR¿ in the metabolic reprogramming associated with breast tumor progression. Aim 2: Define the role of ERR¿ in establishing and maintaining the tumor microenvironment in breast cancer. Aim 3: Define the impact of ERR¿ on growth and metastasis in established models of breast cancer. Expected outcomes: Our data suggests that inhibition of ERR¿ may have utility in the treatment of ER¿- negative, HER2 positive, and triple negative cancers where its activity is particularly evident. The studies outlined will advance this therapeutic approach by defining the importance of ERR¿ as an integrator of cancer cell metabolism and of other non-metabolic pathways of pathological importance in cancer. We believe that the metabolic pathways upregulated by ERR¿ in cancer are also manifest in healthy tissues with a high metabolic demand, and, thus, the insights from this work will be instructive as to the role of ERR¿ in normal physiology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Manipulating normal estrogen physiology as a therapeutic approach in cancer
-
批准号:10561945
-
项目类别:
-
资助金额:$55.86万
-
财政年份:2023
-
负责人:Donald P McDonnell
-
依托单位:
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
-
批准号:10418461
-
项目类别:
-
资助金额:$66.5万
-
财政年份:2022
-
负责人:Donald P McDonnell
-
依托单位:
Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics
-
批准号:10510732
-
项目类别:
-
资助金额:$25.49万
-
财政年份:2022
-
负责人:Donald P McDonnell
-
依托单位:
Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics
-
批准号:10684832
-
项目类别:
-
资助金额:$27.24万
-
财政年份:2022
-
负责人:Donald P McDonnell
-
依托单位:
Validation of the Estrogen Related Receptor as a therapeutic target in cancer
-
批准号:8012324
-
项目类别:
-
资助金额:$8.93万
-
财政年份:2010
-
负责人:Donald P McDonnell
-
依托单位:
The pharmacological actions of antiprogestins in uterine fibroids
-
批准号:7504946
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2009
-
负责人:Donald P McDonnell
-
依托单位:
The pharmacological actions of antiprogestins in uterine fibroids
-
批准号:7900905
-
项目类别:
-
资助金额:$41.54万
-
财政年份:2009
-
负责人:Donald P McDonnell
-
依托单位:
Validation of the Estrogen Related Receptor as a therapeutic target in cancer
-
批准号:7541738
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2007
-
负责人:Donald P McDonnell
-
依托单位:
Validation of the Estrogen Related Receptor as a therapeutic target in cancer
-
批准号:7372733
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2007
-
负责人:Donald P McDonnell
-
依托单位:
Validation of the Estrogen Related Receptor as a therapeutic target in cancer
-
批准号:8019621
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2007
-
负责人:Donald P McDonnell
-
依托单位:
Validation of the Estrogen Related Receptor as a therapeutic target in cancer
-
批准号:8204677
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2007
-
负责人:Donald P McDonnell
-
依托单位:
The role of ERRalpha/PGC-1 in disease pathogenesis
-
批准号:9195702
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2006
-
负责人:Donald P McDonnell
-
依托单位:
The role of ERRalpha/PGC-1 in disease pathogenesis
-
批准号:8610906
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2006
-
负责人:Donald P McDonnell
-
依托单位:
The role of ERRalpha/PGC-1 in disease pathogenesis
-
批准号:8997471
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2006
-
负责人:Donald P McDonnell
-
依托单位:
Conference on Tissue-Selective Nuclear Receptors
-
批准号:6887878
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2004
-
负责人:Donald P McDonnell
-
依托单位:
Nuclear Receptors: Steroid Sisters
-
批准号:6748025
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2004
-
负责人:Donald P McDonnell
-
依托单位:
Molecular Determinants of Androgen Receptor Pharmacology
-
批准号:7580170
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2003
-
负责人:Donald P McDonnell
-
依托单位:
Molecular Determinants of Androgen Receptor Pharmacology
-
批准号:7074657
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2003
-
负责人:Donald P McDonnell
-
依托单位:
Molecular Determinants of Androgen Receptor Pharmacology
-
批准号:7996009
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2003
-
负责人:Donald P McDonnell
-
依托单位:
Molecular Determinants of Androgen Receptor Pharmacology
-
批准号:6896157
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2003
-
负责人:Donald P McDonnell
-
依托单位:
海外基金